We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Venetoclax

Expanded access is currently available for this treatment.
Verified April 2017 by AbbVie
Sponsor:
ClinicalTrials.gov Identifier:
NCT03123029
First Posted: April 21, 2017
Last Update Posted: April 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie
April 18, 2017
April 21, 2017
April 21, 2017
 
Expanded Access to Venetoclax
Expanded Access to Venetoclax
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Not Provided
Expanded Access
Individual Patients
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma
  • Acute Myeloid Leukemia (AML)
  • Non-Hodgkin's Lymphoma
Drug: Venetoclax
Venetoclax will be administered orally.
Other Names:
  • ABT-199
  • GDC-0199
Not Provided
 
Available
  • The participant must not be eligible for a venetoclax clinical trial.
  • Pediatric participants may be evaluated on a case by case basis.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: AbbVie_Call Center 847-283-8955 abbvieclinicaltrials@abbvie.com
Not Provided
 
 
NCT03123029
C16-431
AbbVie
AbbVie
Not Provided
Study Director: AbbVie Inc. AbbVie
AbbVie
April 2017